Form 4: Pacira CMO's Stock Holdings Update

Pacira BioSciences' Chief Medical Officer, Jonathan Slonin, reported changes in his beneficial ownership, including shares withheld for taxes and shares acquired via an employee stock purchase plan.

Summary

• Jonathan Slonin, Chief Medical Officer of Pacira BioSciences, Inc. (PCRX), reported changes in his beneficial ownership of common stock.
• On August 1, 2025, 315 shares were withheld by the issuer at a price of $22.07 per share to cover tax withholding obligations related to the vesting of a restricted stock unit award.
• The reported beneficial ownership after this transaction is 182,327.009 shares of common stock.
• This total includes 682.498 shares of common stock acquired under the issuer's employee stock purchase plan in June 2025.

Sentiment

Score: 6

Explanation: The filing reports routine insider transactions. The acquisition of shares through an ESPP is a minor positive, indicating continued participation, while the tax withholding is a neutral, standard event. No significant positive or negative operational news is present.

Positives

• Acquisition of 682.498 shares through the employee stock purchase plan indicates continued participation and potential confidence in the company by the Chief Medical Officer.

Negatives

• Disposal of 315 shares to cover tax withholding obligations, while a standard practice for vested equity, reduces the direct beneficial ownership.

Future Outlook

The filing is a transactional report and does not provide forward-looking statements or guidance regarding the company's future performance or strategic direction.

Industry Context

This filing is a routine insider transaction report and does not provide specific insights into broader industry trends or competitive landscape. It reflects an individual executive's stock activity within the pharmaceutical/biotechnology sector.

Comparison to Industry Standards

• This Form 4 filing details routine insider transactions (tax withholding and ESPP acquisition) which are standard practices across publicly traded companies.
• There are no specific comparable companies, projects, or results mentioned within this filing to assess against global benchmarks.

Stakeholder Impact

• The reported transactions have a minimal direct impact on shareholders, as they represent routine adjustments to an executive's equity holdings. The acquisition of shares via ESPP could be seen as a minor positive signal of executive alignment with shareholder interests.
• No direct impact on employees, customers, suppliers, or creditors is indicated by this filing.

Key Dates

Recommendation

This Form 4 filing details routine insider transactions (shares withheld for taxes and ESPP acquisition) and does not contain any new material information that would warrant a change in investment recommendation. It provides no insights into the company's operational performance, strategic direction, or financial health that would influence a 'buy' or 'sell' decision. Therefore, a 'hold' recommendation is appropriate as the filing itself does not present a compelling reason to alter an existing position.

Keywords

Pacira BioSciences, PCRX, Jonathan Slonin, Chief Medical Officer, SEC Form 4, Beneficial Ownership, Stock Holdings, Restricted Stock Units, Employee Stock Purchase Plan, Insider Trading